Yousif Capital Management LLC lessened its stake in shares of McKesson Co. (NYSE:MCK – Free Report) by 10.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,482 shares of the company’s stock after selling 2,340 shares during the quarter. Yousif Capital Management LLC’s holdings in McKesson were worth $11,673,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its holdings in McKesson by 2.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 4,943,520 shares of the company’s stock worth $2,444,175,000 after acquiring an additional 138,685 shares during the last quarter. FMR LLC boosted its holdings in shares of McKesson by 17.3% during the third quarter. FMR LLC now owns 2,968,239 shares of the company’s stock worth $1,467,557,000 after purchasing an additional 438,423 shares during the period. Geode Capital Management LLC grew its stake in shares of McKesson by 1.0% in the third quarter. Geode Capital Management LLC now owns 2,653,288 shares of the company’s stock worth $1,306,873,000 after purchasing an additional 26,299 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in McKesson by 55.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company’s stock valued at $588,048,000 after purchasing an additional 425,875 shares during the period. Finally, Nordea Investment Management AB raised its position in McKesson by 20.0% during the 4th quarter. Nordea Investment Management AB now owns 975,935 shares of the company’s stock valued at $558,606,000 after purchasing an additional 162,688 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.
Insider Activity at McKesson
In other news, EVP Leann B. Smith sold 579 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the transaction, the executive vice president now owns 864 shares in the company, valued at $494,890.56. The trade was a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.11% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on McKesson
McKesson Trading Up 0.3 %
McKesson stock opened at $605.37 on Thursday. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $637.51. The company has a market capitalization of $76.85 billion, a price-to-earnings ratio of 31.35, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The business’s fifty day simple moving average is $590.03 and its two-hundred day simple moving average is $562.26.
McKesson (NYSE:MCK – Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. On average, equities research analysts predict that McKesson Co. will post 32.72 EPS for the current year.
McKesson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.47%. The ex-dividend date is Monday, March 3rd. McKesson’s dividend payout ratio (DPR) is currently 14.71%.
McKesson Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read More
- Five stocks we like better than McKesson
- 5 Top Rated Dividend Stocks to Consider
- 3 Must-Have ETFs Set to Dominate This Quarter
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What Are Growth Stocks and Investing in Them
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.